Genmab and Lundbeck implement sustainability goals in executive incentive programs
Genmab and Lundbeck currently belong in the exclusive club of C25 companies that are integrating ESG indicators into their management incentive compensation plans.
BY ØKONOMISK UGEBREV, PROCESSED BY RITZAU, TRANSLATED BY NIELSINE NIELSEN
Prominent pharmaceutical industry figures like Jan van de Winkel and Deborah Dunsire from Genmab and Lundbeck, respectively, are joining top executives at Novo Nordisk and Novozymes in a small but exclusive club of C25 companies which integrate ESG indicators into their management incentive schemes.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biomarin awaits crucial approvals and flat growth in 2021
For subscribers
Generics companies get green light for Lundbeck drug
For subscribers
